Lynda Roman
Overview
Explore the profile of Lynda Roman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
514
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee P, Brunette L, Sriprasert I, Eloustaz M, Deshpande R, Adams C, et al.
Cureus
. 2023 Dec;
15(11):e49183.
PMID: 38130508
Study Objective: This study aimed to determine the effect of the implementation of the Enhanced Recovery After Surgery (ERAS) protocol among patients receiving minimally invasive gynecologic surgery. Design And Setting:...
2.
Buckley D, Lewinger J, Gooden G, Spillman M, Neuman M, Guo X, et al.
Clin Cancer Res
. 2023 Oct;
29(24):5196-5206.
PMID: 37812492
Purpose: High-grade serous ovarian carcinoma (HGSOC) is the most lethal epithelial ovarian cancer (EOC) and is often diagnosed at late stage. In women with a known pelvic mass, surgery followed...
3.
Blake E, Ross M, Ross M, Matsuo K, Silverstein E, Torno L, et al.
Arch Gynecol Obstet
. 2021 Aug;
305(2):439-447.
PMID: 34392396
Objective: To validate our previous findings of high-level EGFR expression in GCCC using an expanded cohort of specimens and to further examine the molecular and cellular features of this aggressive...
4.
Matsuo K, Matsuzaki S, Mandelbaum R, Klar M, Roman L
Int J Gynecol Cancer
. 2020 Aug;
30(9):1464.
PMID: 32747409
No abstract available.
5.
Matsuo K, Mandelbaum R, Ciccone M, Khoshchehreh M, Pursuwani H, Morocco E, et al.
Int J Gynecol Cancer
. 2020 May;
30(9):1331-1339.
PMID: 32376736
Introduction: Previous studies have suggested that metformin use may enhance the therapeutic effect of progestin therapy for endometrial hyperplasia or malignancy. However, it is not known how the impact of...
6.
Lee A, Wu A, Wiensch A, Mukherjee B, Terry K, Harris H, et al.
Epidemiology
. 2020 Feb;
31(3):402-408.
PMID: 32028322
Background: Menopausal estrogen-alone therapy is a risk factor for endometrial and ovarian cancers. When a progestin is included with the estrogen daily (continuous estrogen-progestin combined therapy), there is no increased...
7.
Perkins V, Moore K, Vesely S, Matsuo K, Mostofizadeh S, Sims T, et al.
Gynecol Oncol
. 2019 Dec;
156(1):100-106.
PMID: 31810653
Objectives: Chemotherapy is the standard treatment in stage IVB cervical cancer (CC). However, given that many women have a significant pelvic disease burden, whole pelvic radiation (WPR) in addition to...
8.
Xiong S, Mhawech-Fauceglia P, Tsao-Wei D, Roman L, Gaur R, Epstein A, et al.
BMC Cancer
. 2019 Nov;
19(1):1114.
PMID: 31729966
We investigated the association of LHR expression in epithelial ovarian cancer (OC) with clinical and pathologic characteristics of patients. LHR expression was examined immunohistochemically using tissue microarrays (TMAs) of specimens...
9.
Blake E, Ross M, Ihenacho U, Figueroa L, Silverstein E, Flink D, et al.
Gynecol Oncol Rep
. 2019 Nov;
30:100497.
PMID: 31692541
Objectives: To evaluate interest in and patterns of use of non-prescription cannabis products for symptom management amongst gynecologic cancer patients living in states with legal access to medical and recreational...
10.
Matei D, Ghamande S, Roman L, Secord A, Nemunaitis J, Markham M, et al.
Clin Cancer Res
. 2018 Mar;
24(10):2285-2293.
PMID: 29500276
Epigenetic changes are implicated in acquired resistance to platinum. Guadecitabine is a next-generation hypomethylating agent (HMA). Here, we report the clinical results, along with pharmacokinetic (PK) and pharmacodynamic analyses of...